L Zhou1,2,3, X Chen1,2,4, J Yan1,2, M Li1,2, T Liu1, C Zhu2, G Pan2, Q Guo2, H Yang5,6, M Pei7, F He8,9. 1. Department of Orthopaedics, The First Affiliated Hospital of Soochow University, Soochow University, No. 188 Shizi Street, Suzhou, Jiangsu, 215006, China. 2. Orthopaedic Institute, Medical College, Soochow University, No.708 Renmin Road, Suzhou, Jiangsu, 215007, China. 3. Department of Orthopaedics, Suzhou Science & Technology Town Hospital, Suzhou, 215153, China. 4. School of Biology and Basic Medical Sciences, Medical College, Soochow University, Suzhou, 215123, China. 5. Department of Orthopaedics, The First Affiliated Hospital of Soochow University, Soochow University, No. 188 Shizi Street, Suzhou, Jiangsu, 215006, China. hlyang@suda.edu.cn. 6. Orthopaedic Institute, Medical College, Soochow University, No.708 Renmin Road, Suzhou, Jiangsu, 215007, China. hlyang@suda.edu.cn. 7. Stem Cell and Tissue Engineering Laboratory, Department of Orthopaedics and Division of Exercise Physiology, West Virginia University, Morgantown, WV, 26505, USA. 8. Department of Orthopaedics, The First Affiliated Hospital of Soochow University, Soochow University, No. 188 Shizi Street, Suzhou, Jiangsu, 215006, China. fanhe@suda.edu.cn. 9. Orthopaedic Institute, Medical College, Soochow University, No.708 Renmin Road, Suzhou, Jiangsu, 215007, China. fanhe@suda.edu.cn.
Abstract
Osteoporosis is linked to age-related decline of melatonin production; however, the direct effects of melatonin on osteoclastogenesis remain unknown. Our study demonstrates that melatonin at pharmacological concentrations, rather than at physiological concentrations, significantly inhibits osteoclastogenesis. Melatonin-mediated anti-osteoclastogenesis involves a reactive oxygen species (ROS)-mediated but not a silent information regulator type 1 (SIRT1)-independent pathway. INTRODUCTION: Osteoporosis is a bone disorder linked to impaired bone formation and excessive bone resorption. Melatonin has been suggested to treat osteoporosis due to its beneficial actions on osteoblast differentiation. However, the direct effects of melatonin on osteoclastogenesis in bone marrow monocytes (BMMs) remain unknown. This study was to investigate whether melatonin at either physiological or pharmacological concentrations could affect osteoclast differentiation. METHODS: Primary BMMs were isolated from the femurs and tibias of C57BL/6 mice and were induced toward multinucleated osteoclasts, in the presence of melatonin at either physiological (0.01 to 10 nM) or pharmacological (1 to 100 μM) concentrations. Tartrate-resistant acid phosphatase (TRAP) staining was used to label multinucleated osteoclasts and the levels of osteoclast-specific genes were evaluated. To further explore the underlying mechanisms, the roles of silent information regulator type 1 (SIRT1) and reactive oxygen species (ROS) were evaluated. RESULTS: We found that melatonin at pharmacological concentrations, rather than at physiological concentrations, significantly inhibited osteoclast formation in a dose-dependent manner. The number of TRAP-positive cells and the gene expression of osteoclast-specific markers were significantly downregulated in melatonin-treated BMMs. The melatonin-mediated repression of osteoclast differentiation involved the inhibition of the nuclear factor κ-light-chain-enhancer of activated B cells (NF-κB) signaling pathway. The treatment with SIRT1 inhibitors did not affect osteoclast differentiation but, when supplemented with exogenous hydrogen peroxide, a partial rescue of melatonin-suppressed osteoclastogenesis was observed. CONCLUSION: Melatonin at pharmacological doses directly inhibited osteoclastogenesis of BMMs by a ROS-mediated but not a SIRT1-independent pathway.
Osteoporosis is linked to age-related decline of melatonin production; however, the direct effects of melatonin on osteoclastogenesis remain unknown. Our study demonstrates that melatonin at pharmacological concentrations, rather than at physiological concentrations, significantly inhibits osteoclastogenesis. Melatonin-mediated anti-osteoclastogenesis involves a reactive oxygen species (ROS)-mediated but not a silent information regulator type 1 (SIRT1)-independent pathway. INTRODUCTION:Osteoporosis is a bone disorder linked to impaired bone formation and excessive bone resorption. Melatonin has been suggested to treat osteoporosis due to its beneficial actions on osteoblast differentiation. However, the direct effects of melatonin on osteoclastogenesis in bone marrow monocytes (BMMs) remain unknown. This study was to investigate whether melatonin at either physiological or pharmacological concentrations could affect osteoclast differentiation. METHODS: Primary BMMs were isolated from the femurs and tibias of C57BL/6 mice and were induced toward multinucleated osteoclasts, in the presence of melatonin at either physiological (0.01 to 10 nM) or pharmacological (1 to 100 μM) concentrations. Tartrate-resistant acid phosphatase (TRAP) staining was used to label multinucleated osteoclasts and the levels of osteoclast-specific genes were evaluated. To further explore the underlying mechanisms, the roles of silent information regulator type 1 (SIRT1) and reactive oxygen species (ROS) were evaluated. RESULTS: We found that melatonin at pharmacological concentrations, rather than at physiological concentrations, significantly inhibited osteoclast formation in a dose-dependent manner. The number of TRAP-positive cells and the gene expression of osteoclast-specific markers were significantly downregulated in melatonin-treated BMMs. The melatonin-mediated repression of osteoclast differentiation involved the inhibition of the nuclear factor κ-light-chain-enhancer of activated B cells (NF-κB) signaling pathway. The treatment with SIRT1 inhibitors did not affect osteoclast differentiation but, when supplemented with exogenous hydrogen peroxide, a partial rescue of melatonin-suppressed osteoclastogenesis was observed. CONCLUSION:Melatonin at pharmacological doses directly inhibited osteoclastogenesis of BMMs by a ROS-mediated but not a SIRT1-independent pathway.
Entities:
Keywords:
Bone marrow monocytes; Melatonin; Osteoclasts; Osteoporosis; ROS; SIRT1
Authors: Ki Hyun Baek; Ki Won Oh; Won Young Lee; Seong Su Lee; Mee Kyoung Kim; Hyuk Sang Kwon; Eun Jung Rhee; Je Ho Han; Ki Ho Song; Bong Yun Cha; Kwang Woo Lee; Moo Il Kang Journal: Calcif Tissue Int Date: 2010-07-08 Impact factor: 4.333
Authors: Lucien C Manchester; Ana Coto-Montes; Jose Antonio Boga; Lars Peter H Andersen; Zhou Zhou; Annia Galano; Jerry Vriend; Dun-Xian Tan; Russel J Reiter Journal: J Pineal Res Date: 2015-09-11 Impact factor: 13.007
Authors: Long Zhou; Xi Chen; Tao Liu; Yihong Gong; Sijin Chen; Guoqing Pan; Wenguo Cui; Zong-Ping Luo; Ming Pei; Huilin Yang; Fan He Journal: J Pineal Res Date: 2015-07-07 Impact factor: 13.007
Authors: Tina Histing; Christina Anton; Claudia Scheuer; Patric Garcia; Joerg H Holstein; Moritz Klein; Romano Matthys; Tim Pohlemann; Michael D Menger Journal: J Surg Res Date: 2010-09-21 Impact factor: 2.192
Authors: Yan Xu; Leslie R Morse; Raquel Assed Bezerra da Silva; Paul R Odgren; Hajime Sasaki; Philip Stashenko; Ricardo A Battaglino Journal: Antioxid Redox Signal Date: 2010-07-01 Impact factor: 8.401
Authors: Mao Li; Xi Chen; Jinku Yan; Long Zhou; Yifan Wang; Fan He; Jun Lin; Caihong Zhu; Guoqing Pan; Jia Yu; Ming Pei; Huilin Yang; Tao Liu Journal: Acta Biomater Date: 2018-03-08 Impact factor: 8.947